Inoperable HCC

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Inoperable HCC trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT06077591

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided The…

Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within thei…

Hong Kong40 participantsStarted 2024-10-18

Treatment: Patient-Derived Tumor Organoids

All recent trials (30 shown)

Active — Not RecruitingPhase 3

NCT05016245

MANDARIN (S6371)

To evaluate the efficacy and safety of TheraSphereTM yttrium \[90Y\] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.

China92 participantsStarted 2021-09-13

Treatment: TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE)

CompletedNot Applicable

NCT01556490

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sor…

United States526 participantsStarted 2012-03

Treatment: TheraSphere

Inoperable HCC

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided The…

All recent trials (30 shown)

MANDARIN (S6371)

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided The…

All recent trials (30 shown)

MANDARIN (S6371)

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Y-90 Versus SBRT for Inoperable HCC

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Ther…

ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma

A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC

Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy

A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (…

Hepatocellular Carcinoma (HCC)_Torisel_

Dynamic Contrast Enhanced HCC SABR Liver Study

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma